BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Niu ZS, Wang WH. Circular RNAs in hepatocellular carcinoma: Recent advances. World J Gastrointest Oncol 2022; 14(6): 1067-1085 [DOI: 10.4251/wjgo.v14.i6.1067] [Reference Citation Analysis]
2 Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective. Cancers (Basel) 2021;13:3651. [PMID: 34359553 DOI: 10.3390/cancers13153651] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yan Y, Liang Q, Xu Z, Huang J, Chen X, Cai Y, Peng B, Yi Q. Downregulated Ferroptosis-Related Gene STEAP3 as a Novel Diagnostic and Prognostic Target for Hepatocellular Carcinoma and Its Roles in Immune Regulation. Front Cell Dev Biol 2021;9:743046. [PMID: 34790664 DOI: 10.3389/fcell.2021.743046] [Reference Citation Analysis]
5 Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157 [DOI: 10.4254/wjh.v14.i1.140] [Reference Citation Analysis]
6 Dong M, Wen X, He X, Ren J, Yu H, Qin Y, Yang Z, Yang M, Zhou C, Zhang H, Cheng S, Chen J. HBx Mediated Increase of DDX17 Contributes to HBV-Related Hepatocellular Carcinoma Tumorigenesis. Front Immunol 2022;13:871558. [DOI: 10.3389/fimmu.2022.871558] [Reference Citation Analysis]
7 Pourhamzeh M, Asadian S, Mirzaei H, Minaei A, Shahriari E, Shpichka A, Es HA, Timashev P, Hassan M, Vosough M. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Mol Cell Biochem 2022. [PMID: 35708866 DOI: 10.1007/s11010-022-04483-4] [Reference Citation Analysis]
8 Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021; 13(6): 509-535 [PMID: 34163570 DOI: 10.4251/wjgo.v13.i6.509] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Vène E, Jarnouen K, Ribault C, Vlach M, Verres Y, Bourgeois M, Lepareur N, Cammas-marion S, Loyer P. Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl malate)-Based Nanoparticles in Human Hepatoma Cells. Pharmaceutics 2022;14:804. [DOI: 10.3390/pharmaceutics14040804] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Reference Citation Analysis]
12 Tischfield DJ, Gurevich A, Johnson O, Gatmaytan I, Nadolski GJ, Soulen MC, Kaplan DE, Furth E, Hunt SJ, Gade TPF. Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model. Radiology 2022;:211028. [PMID: 35014906 DOI: 10.1148/radiol.211028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Weinmann A, Galle PR. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Curr Oncol 2020;27:S152-64. [PMID: 33343209 DOI: 10.3747/co.27.7315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tian X, Lian J, Li X, Chen X, Yuan H, Zhou M, Liu F. Intra-arterial delivery of doxorubicin-loaded hollow gold nanospheres—photothermal ablation and chemoembolisation therapy in a rabbit VX2 liver cancer model. Journal of Experimental Nanoscience 2022;17:439-50. [DOI: 10.1080/17458080.2022.2091132] [Reference Citation Analysis]
15 Yang Y, Gao L, Chen J, Xiao W, Liu R, Kan H. Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma. Bioengineered 2022;13:9211-31. [PMID: 35436411 DOI: 10.1080/21655979.2022.2057896] [Reference Citation Analysis]
16 Zhang T, Zhou H, Wang K, Wang X, Wang M, Zhao W, Xi X, Li Y, Cai M, Zhao W, Xu Y, Shao R. Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development. Biomed Pharmacother 2022;147:112616. [PMID: 35008001 DOI: 10.1016/j.biopha.2022.112616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Marié C, Fouquet G, Courtois A, Amrathlal RS, Jankovsky N, Ouled-Haddou H, Tebbakha R, Bouhlal H, Nguyen-Khac É, Naassila M, Marcq I. Mechanisms of chronic alcohol exposure-induced aggressiveness in cellular model of HCC and recovery after alcohol withdrawal. Cell Mol Life Sci 2022;79:366. [PMID: 35713728 DOI: 10.1007/s00018-022-04387-y] [Reference Citation Analysis]
18 Koskinas J, Armakolas A. Ariadne's Thread in the Network of Hepatocellular Carcinoma Immunobiology. J Clin Transl Hepatol 2021;9:279-80. [PMID: 34221912 DOI: 10.14218/JCTH.2021.00140] [Reference Citation Analysis]
19 Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers (Basel) 2022;14:2959. [PMID: 35740624 DOI: 10.3390/cancers14122959] [Reference Citation Analysis]
20 Brossard C, Vlach M, Vène E, Ribault C, Dorcet V, Noiret N, Loyer P, Lepareur N, Cammas-Marion S. Synthesis of Poly(Malic Acid) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells. Nanomaterials (Basel) 2021;11:958. [PMID: 33918663 DOI: 10.3390/nano11040958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ronnebaum S, Aly A, Patel D, Benavente F, Rueda JD. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepat Oncol 2022;9:HEP41. [PMID: 34765109 DOI: 10.2217/hep-2021-0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Qayum K, Kar I, Rashid U, Nawaz G, Krishnakumar P, Sudarshan V, Syed A. Effects of surgery, chemotherapy, and radiation on hepatocellular carcinoma patients: A SEER-based study. Ann Med Surg (Lond) 2021;69:102782. [PMID: 34522376 DOI: 10.1016/j.amsu.2021.102782] [Reference Citation Analysis]